Drug intelligence / Profile preview

xiaoshengliu decoction

Development stage: Preclinical
Lead developer: National hi-tech research and development program
Administration: Oral

Overview

Xiaoshengliu decoction is a traditional Chinese medicine compound. It is being investigated for its potential to improve suboptimal health status, as evidenced by its use in a clinical trial where it was administered orally twice a day for four weeks to individuals with confirmed suboptimal health status.

Targets

RAF1 (c-Raf-1 (Y340D/Y341D))ESR1 (ERα)CDK2 (Cyclin-dependent kinase 2)GSK3 (Glycogen synthase kinase 3 beta)

Beyond the preview

Go deeper on xiaoshengliu decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xiaoshengliu decoction.

Explore the full profile